

# THE ASSOCIATION BETWEEN THE CHANGE IN DIRECTLY MEASURED CARDIORESPIRATORY FITNESS ACROSS TIME AND MORTALITY RISK

Short Title: Fitness Changes and Mortality

Mary T. Imboden<sup>1</sup>, Matthew P. Harber<sup>1</sup>, Mitchell H. Whaley<sup>1</sup>, W. Holmes Finch<sup>1</sup>, Derron L. Bishop<sup>2</sup>, Bradley S. Fleenor<sup>1</sup>, Leonard A. Kaminsky<sup>1</sup>

<sup>1</sup>Ball State University, Muncie, Indiana

<sup>2</sup>Indiana University School of Medicine, Muncie, Indiana

Corresponding Author:

Leonard A. Kaminsky

Address: Ball State University, Fisher Institute of Health and Well-Being,  
2000 University Avenue, Muncie, IN 47306

Phone: 765-285-8158

Fax: 765-285-8237

Email: kaminskyla@bsu.edu

Word count: 3621

Key Words: Cardiopulmonary exercise testing, risk reduction, exercise training, cancer, cardiovascular disease

Funding: Support for this project was provided, in part, from an American Heart Association Award #AIREA33930023 (M. Harber, PI).

Disclosures: L. Kaminsky serves as a Scientific Advisor for ENDO Medical, Inc.

**Acknowledgements:** The authors thank Lynn Witty, MD for her assistance in providing clinical feedback regarding data interpretation and for editorial feedback in the preparation of this manuscript.

Current Affiliation: Mary T. Imboden, Ph.D. is currently an Assistant Professor at George Fox University.

### List of Abbreviations

ACLS - Aerobic Center Longitudinal Study

AHA – American Heart Association

ANOVA - analysis of variance

BALL ST - Ball State Addult fitness Longitudinal Lifestyle Study

CI – confidence interval

CPX - cardiopulmonary exercise testing

CPX-CRF directly measured cardiorespiratory fitness obtained from cardiopulmonary exercise testing

CRF - cardiorespiratory fitness

CRF<sub>e</sub> - estimated CRF

CVD - cardiovascular disease

HR - hazard ratio

ICD - International Classification of Diseases

MET – metabolic equivalent

NDI - National Death Index

PA - physical activity

VO<sub>2peak</sub> - peak oxygen consumption

## Abstract

**Background:** The relationship between cardiorespiratory fitness (CRF) and mortality risk has typically been assessed using a single measurement, though some evidence suggests the change in CRF over time influences risk. This evidence is predominantly based on studies using estimated CRF (CRF<sub>e</sub>). The strength of this relationship using change in directly measured CRF over time in apparently healthy men and women is not well understood. **Purpose:** To examine the association of change in CRF over time, measured using cardiopulmonary exercise testing (CPX), with all-cause and disease-specific mortality and to compare baseline and subsequent CRF measurements as predictors of all-cause mortality. **Methods:** Participants included 833 apparently healthy men and women ( $42.9 \pm 10.8$  years) who underwent two maximal CPXs, the second CPX being  $\geq 1$  year following the baseline assessment (mean 8.6 years, range 1.0 to 40.3 years). Participants were followed for up to 17.7 (SD 11.8) years for all-cause-, cardiovascular disease- (CVD), and cancer mortality. Cox-proportional hazard models were performed to determine the association between the change in CRF, computed as visit 1 (CPX1) peak oxygen consumption ( $\text{VO}_{2\text{peak}}$  [ $\text{mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ ]) – visit 2 (CPX2)  $\text{VO}_{2\text{peak}}$ , and mortality outcomes. A Wald-Chi square test of equality was used to compare the strength of CPX1 to CPX2  $\text{VO}_{2\text{peak}}$  in predicting mortality. **Results:** During follow-up, 172 participants died. Overall, the change in CPX-CRF was inversely related to all-cause, CVD, and cancer mortality ( $p < 0.05$ ). Each  $1 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$  increase was associated with a ~ 11, 15, and 16% (all  $p < 0.001$ ) reduction in all-cause, CVD, and cancer mortality, respectively. The inverse relationship between CRF and all-cause mortality was significant ( $p < 0.05$ ) when men and women were examined independently, after adjusting for years since first CPX, baseline  $\text{VO}_{2\text{peak}}$ , and age. Further, the Wald Chi-square test of equality found CPX2  $\text{VO}_{2\text{peak}}$  to be a significantly stronger predictor of all-cause mortality than CPX1  $\text{VO}_{2\text{peak}}$  ( $p < 0.05$ ). **Conclusion:** The change in CRF over time was inversely related to

mortality outcomes, and mortality was better predicted by CRF measured at subsequent test than CPX1 CRF. These findings emphasize the importance of adopting lifestyle behaviors that promote CRF, as well as support the need for routine assessment of CRF in clinical practice to better assess risk.

## Introduction

Healthy lifestyles are gaining increased recognition in clinical and public health settings.<sup>1</sup> Cardiorespiratory fitness (CRF) is a key outcome measure associated with healthy lifestyles.<sup>2</sup> Evidence has consistently shown CRF to be a strong and independent predictor of chronic disease, including CVD, cancer, and all-cause mortality.<sup>3-7</sup> Several studies have shown CRF to be a better predictor of health outcomes in both healthy and clinical populations than traditional cardiovascular disease (CVD) risk factors that are commonly assessed clinically.<sup>4,5</sup>

CRF is a modifiable risk factor that is influenced by lifestyle and health parameters, including exercise training status.<sup>8-11</sup> Improvements in CRF have been shown to result in beneficial changes in traditional risk factors and health.<sup>12-14</sup> Additionally, there is growing evidence suggesting changes in estimated CRF (CRF<sub>e</sub>) over time (>1 year), are associated with changes in mortality risk.<sup>15-21</sup> Since CRF may change over time, the routine assessment of CRF may have stronger prognostic value and use as a mortality risk assessment tool than a single CRF measurement.

Past studies assessing the association between the change in CRF over time and mortality have predominately used CRF<sub>e</sub> from exercise test workload or duration.<sup>4, 15-17, 19-21</sup> Additionally, past studies have only assessed men and used cohort specific reference values to define CRF thresholds.<sup>4, 15-17, 19, 21</sup> These factors may limit the generalizability of the findings and clear understanding of this relationship.<sup>22, 23</sup> Further, the estimation errors associated with CRF<sub>e</sub> may impact an individual's risk assessment, reducing its sensitivity.

Recent scientific statements and reviews have emphasized the need for more studies assessing the association between directly measured CRF, obtained from cardiopulmonary

exercise testing (CPX-CRF) which is considered the gold standard method, and mortality outcomes.<sup>24, 25</sup> Only two studies have used CPX-CRF as a baseline measure and only one study has examined the association between the change in CPX-CRF and mortality apparently healthy individuals.<sup>3, 15</sup> Laukkanen et al studied 579 men (age range: 42-60 y) from eastern Finland who performed two CPX with cycle ergometry 11-years apart.<sup>15</sup> After a median follow-up of 13.3 years from the second CPX, a graded relationship was found, where each 1 MET higher change was associated with a 30% lower risk of all-cause mortality. The findings from this study of middle-aged Finnish men tested using a cycle ergometer protocol may not be generalizable to other populations, including women, nor to CPX-CRF measured using treadmill as the mode for testing. Therefore, the primary aim of this study was to examine the association of the change in CPX-CRF over time (>1 year between CRF measures) with all-cause and disease-specific mortality in a cohort of apparently healthy men and women. Secondly, this study sought to determine if a second measure of CRF, > 1 year after the first, improves the prediction of mortality risk across time above a single measure.

## Methods

The study cohort included 833 apparently healthy participants (552 men, 281 women; baseline mean age:  $42.9 \pm 10.8$ , range 18.0 - 82.0 years) obtained from the Ball State Addult fitness Longitudinal Lifestyle Study (BALL ST) cohort. Participants were self-referred either to the Ball State University-Adult Physical Fitness Program, a community-based exercise program or were research subjects in clinical exercise physiology related studies who gave written informed consent for their data to be used for research. Participants were considered apparently healthy, as all were free from known CVD (history of cardiac arrest, coronary artery disease, heart failure, myocardial infarction, and stroke) and cancer at baseline or follow-up. CVD

diagnosis was self-reported and verified by written physician confirmation. All participants completed two health and fitness assessments between 1969 and 2017, each including a CPX achieving a peak effort criteria of a respiratory exchange ratio  $\geq 1.0$  during both CPX1 and CPX2. These two exams were  $\geq 1$  year apart (mean 8.6 years, range 1.0 to 40.3 years). This study was reviewed by the Ball State University Institutional Review Board and determined exempt as only de-identified data were used.

#### *Resting Health Assessment*

A full description of the procedures involved in the resting health and fitness measurements performed prior to both CPXs have been explained previously.<sup>26, 27</sup> In summary, participants completed a health history questionnaire, providing demographic information, personal and family medical history, medication usage, and lifestyle behaviors. Information gained from the questionnaire was used to screen for medical contraindications and/or physical limitations to CPX.

Lifestyle behaviors of physical activity (PA) and smoking were self-reported. PA status was classified as inactive or active, with active being designated if participants reported engagement in regular PA, meeting the US aerobic PA guidelines for adults.<sup>28</sup> Smoking status was categorized as current smoker, including those that used cigarettes or quit within the past year, or a non-smoker at CPX1.

Clinical measurements including, resting heart rate, blood pressure, anthropometrics (height, weight, waist circumference), 12-lead electrocardiogram, and blood chemistry ( $\geq 8$  hour post-prandial), were performed by trained technicians using standardized laboratory procedures. These measurements were used to determine the presence of risk factors, including obesity,

hypertension, dyslipidemia, and impaired fasting glucose, defined according to current accepted atherosclerotic CVD risk factor criteria.<sup>29</sup>

#### *Assessment of CRF*

A more thorough description of the procedures used to assess CRF have been described previously.<sup>3, 26</sup> In summary, at visit one CPX was performed using a standardized treadmill or cycle protocol, to determine peak oxygen consumption ( $VO_{2peak}$ ). The mode of exercise was chosen based on participant preference, comfort, and the presence of functional limitations as determined through the health history questionnaire. Standardized procedures were followed for metabolic cart calibration and all CPXs were supervised by trained clinical exercise physiologists, with additional medical supervision when appropriate.<sup>30</sup> Participants were encouraged to exercise to volitional fatigue and a respiratory exchange ratio  $\geq 1.0$  was used as an objective indicator of maximal effort.

All participants were re-tested in the Clinical Exercise Physiology laboratory  $\geq 1$  year after their baseline assessment. At this second assessment, both CPX-CRF and resting health and fitness measurements were reassessed following the same standardized procedures and criteria as at baseline. CPX2 was also performed using the same mode of exercise as at CPX1.

#### *Outcomes and Follow-up*

All participants were followed from the date of their CPX2 through 2017 or until date of death for all-cause mortality or December 31, 2016 for disease-specific mortality. The National Death Index (NDI) was the primary data source for obtaining vital status between 1979 and 2016, providing date of death and cause of death. There were no deaths reported in the cohort prior to 1979. Deaths occurring after 2016 (n=10) were confirmed by obituary review. The underlying cause of death determined from the NDI report was coded according to the



International Classification of Diseases (ICD), 9<sup>th</sup> revision, prior to 1999 and the ICD, 10<sup>th</sup> revision, from 1999 to 2016.<sup>31, 32</sup> CVD mortality was defined by the ICD, 9<sup>th</sup> revision codes 390.0 to 449.9 and ICD, 10<sup>th</sup> revision codes I00.0 to I78.9. Cancer mortality was defined by the ICD, 9<sup>th</sup> revision codes 140.0 to 239.0 and ICD, 10<sup>th</sup> revision codes C00.0 to D49.9. For all other ICD codes, cause of death was classified as other.

### *Statistical analysis*

SPSS V. 24 (SPSS, Inc., Chicago, IL) and SAS V. 9.3, were used for all statistical analyses. Descriptive statistics were performed to summarize characteristics of the cohort and a univariate analysis of variance (ANOVA) and chi-square goodness of fit test were used when appropriate to test for significant differences between sexes and vital status (living vs. deceased). Paired T-tests were used to assess the differences between resting health and fitness and CPX measurements. To determine significant differences between CPX1 and CPX2 measures, all descriptive data were normalized to account for differences in the number of years between subject's CPXs. Cox proportional hazard models were used to determine hazard ratios (HR) and 95% confidence intervals (CI) associated with the change in CRF as related to all-cause, CVD, and cancer mortality. Sex-specific hazard models were used to determine the HR related to all-cause mortality according to change in CRF. There were an inadequate number of cases of CVD and cancer specific mortality for sex-specific analyses. CRF was expressed as  $\text{VO}_{2\text{peak}}$  in  $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$  and the continuous change in CRF was computed as the difference in  $\text{VO}_{2\text{peak}}$  between CPX1 and CPX2. The Cox proportional hazard models were fit to the data and run adjusted for years between CPXs (model 1), additionally controlled for CPX1  $\text{VO}_{2\text{peak}}$ , age, and sex (model 2), and then with further adjustment for the change in traditional CVD risk factors (model 3; dyslipidemia, hypertension, impaired fasting glucose, obesity, physical inactivity and smoking

status), which were categorized by the change in each risk factor status between CPX1 and CPX2. The Cox models were obtained separately on a sub-group of the cohort with  $\geq 5$  years (n=491) between CPXs to determine if the relationship remained consistent. A Wald Chi-square test was used to compare the coefficients estimating the relationship of CPX1 CRF to CPX2 CRF with time until death for all-cause mortality. These models were obtained both unadjusted, and then adjusted for years between CPXs, age, and sex.

## Results

Table 1 provides descriptive characteristics of the study cohort at CPX1. Men had a higher absolute CRF than women, however, there were no differences in their values based on age and sex specific reference standards. Additionally, men had a less favorable risk factor profile with a higher prevalence of dyslipidemia, impaired fasting glucose, hypertension, physical inactivity, and smoking ( $p<0.05$ ).

During the follow-up period ( $17.7 \pm 11.8$  years, range: 1.0 - 45.8 years) 172 participants died (132 men, 40 women), with an overall incidence rate of 11.6 deaths per 1,000 person years. The mean age difference for the entire cohort between CPX1 and CPX2 was 8.5 years and the mean change in CRF was  $-1.8 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ . Table 2 provides a comparison of the descriptive characteristics at CPX1 for participants identified as living and deceased at time of follow-up. Overall, at CPX1 participants that died during the follow-up period were older, more likely to be obese, physically inactive, and have dyslipidemia ( $p<0.05$ ). Additionally, at CPX1 women that died during the follow-up period had a significantly higher prevalence of hypertension, but were less likely to have diabetes, and men were more likely to be smokers than their living counterparts ( $p<0.05$ ).

Results from the Cox proportional hazard models assessing risk for all-cause, CVD, and cancer mortality according to per unit change in  $\text{VO}_{2\text{peak}}$  ( $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ) between CPX1 and CPX2 are shown in Table 3a. Overall, there was an inverse relationship between the change in CRF and risk for all-cause, CVD, and cancer mortality after adjusting for years between CPXs (model 1). After further adjustment for baseline  $\text{VO}_{2\text{peak}}$ , age, and sex (model 2), the strength of the association was increased. The inverse association found between the change in CRF and all-cause ( $p<0.01$ ) and disease-specific mortality ( $p<0.05$ ) outcomes remained significant in the multivariable adjusted model (model 3). Specifically, a 1  $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$  increase was found to be associated with ~11%, 15%, and 16% lower risk of all-cause, CVD, and cancer mortality, respectively ( $p<0.001$ ). The inverse relationship between the change in CRF expressed as absolute  $\text{VO}_{2\text{peak}}$  ( $\text{L}\cdot\text{min}^{-1}$ ) and risk for all-cause, CVD, and cancer mortality was significant ( $p<0.05$ ) for each model.

The inverse association between change in  $\text{VO}_{2\text{peak}}$  and all-cause mortality was also present for both men and women, when assessed independently, in both models 1 and 2 (Table 3b). Specifically in model 2, a 1  $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$  increase was found to be associated with approximately a 10% and 11% lower risk of all-cause mortality in men and women, respectively ( $p<0.05$ ). In model 3, following multivariable adjustment the strength of the association remained for men with a 11% lower all-cause mortality risk per 1  $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$  in  $\text{VO}_{2\text{peak}}$ . However, in women, the relationship was attenuated and no longer significant in model 3 ( $p=0.29$ ).

To assess if the relationship remained consistent when assessing the change in CRF over a longer period of time between CPXs, Cox models were obtained on a sub-group with  $\geq 5$  years between CPX1 and CPX2. The inverse association between the change in CRF and all-cause,

CVD, and cancer mortality was also significant in this sub-cohort ( $n=491$ , 104 deceased) in both model 1 (HR=0.956, 95% CI=0.929 - 0.983; HR=0.938, 95% CI=0.890 - 0.988; HR=0.954, 95% CI=0.906 - 0.998, respectively) and in model 2 (HR=0.931, 95% CI=0.897 - 0.967; HR=0.923, 95% CI=0.861 - 0.990; HR=0.925, 95% CI=0.864 - 0.990, respectively). Model 3 showed each 1  $\text{ml}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$  increase in CRF to be significantly associated with 6% lower risk of all-cause mortality ( $p<0.01$ ), and to be marginally associated with an 8.7% and 7.2% lower risk for CVD ( $p=0.09$ ) and cancer mortality ( $p=0.10$ ), respectively.

Results from the Cox proportional hazard model and Wald-chi square test of equality comparing CPX1 CRF to CPX2 CRF as predictors for all-cause mortality are shown in Table 4. CRF measured at CPX2 was found to be a stronger predictor of all-cause mortality than the CPX1 CRF measurement in the unadjusted model, as well as after adjusting for years between CPXs,  $\text{VO}_{2\text{peak}}$  measured at CPX1, age, and sex.

## Discussion

The change in CPX-derived CRF over time in apparently healthy adults was found to be a strong predictor of all-cause, CVD, and cancer mortality. Significant changes in mortality outcomes were seen even with small changes in CRF ( $1 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ) and were independent of changes in traditional CVD risk factors. These results highlight the importance of improving low CRF or maintaining an adequate CRF level throughout the lifespan for both men and women.

The inverse relationship found in the current study using CPX-CRF revealed a stronger association with mortality compared to past studies that used  $\text{CRF}_e$ . Overall, the current study found a 37.8% lower risk in all-cause mortality risk with each MET higher change (10.8% lower risk per  $1 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ; 1 MET =  $3.5 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ), and risk reductions of 35.4% and 27.3% per 1 MET increase in men and women when assessed independently. To place this change in

perspective, each decade of age is associated with >1 MET reduction in CRF. Blair et al. studied 9,777 men from the Aerobic Center Longitudinal Study cohort who performed two preventative maximal exercise tests that were approximately 5 years apart, using CRF<sub>e</sub>.<sup>18</sup> Results showed a 16% reduction in all-cause mortality risk per 1 MET improvement. More recently, Shah et al assessed this relationship in 4,872 young adults (54% women, mean age 24.8 y) that performed two exercise tests, approximately 7 years after baseline.<sup>20</sup> After approximately 20 years of follow-up, results showed that for every one minute reduction in exercise time on the modified Balke protocol (each minute on the exercise test is approximately equal to 1 MET) there was a 21% increase in all-cause mortality. Although differences in the strength of the association between the current study findings and those from these past studies may result from differences in cohort characteristics, the method used to measure CRF may have also impacted the findings.<sup>9</sup>

A common limitation of CRF<sub>e</sub>, is the reported estimation error of approximately  $\pm 1$  to 2 METs.<sup>9, 29, 33, 34</sup> Given that exercise training can result in CRF improvements of this amount,<sup>35</sup> this error may lead to erroneous interpretation of one's change in CRF level (i.e. fit to fit vs. unfit to fit), limiting the strength of the association. These limitations may be overcome by CPX, which provides a direct, quantitative, and more accurate measure of CRF.<sup>22, 23, 36</sup> However, only one other study to date has assessed the relationship between the change in CPX-CRF over time (>1 year) and mortality risk in apparently healthy individuals.<sup>15</sup> This study assessed middle aged men (42 - 60 years) from eastern Finland that performed two CPXs using cycle ergometry with 11 years between tests. Results showed each 1 mL·kg<sup>-1</sup>·min<sup>-1</sup> increase in CPX-CRF was associated with a 10% lower risk of all-cause mortality after adjusting for baseline VO<sub>2peak</sub>. The current results showed similar findings, of an 11.1% and 9.7% lower risk for all-cause mortality per 1 mL·kg<sup>-1</sup>·min<sup>-1</sup> increase in VO<sub>2peak</sub> in the overall cohort and in men only, after similar model

adjustment, respectively. However, CRF is known to be influenced by sex and age.<sup>22, 36-38</sup> We also observed a 11.3% lower risk for all-cause mortality per 1 mL·kg<sup>-1</sup>·min<sup>-1</sup> increase in VO<sub>2peak</sub> in the women. The wider age distribution, use of treadmill as a mode with CPX, and the inclusion of women in the current cohort, helps to advance our understanding of the influence CPX-CRF has on mortality outcomes across the lifespan.

There was also a significant inverse relationship found between the change in CRF and disease-specific mortality in the current cohort. Each 1 mL·kg<sup>-1</sup>·min<sup>-1</sup> increase was associated with ~15% and 16% lower risk of CVD and cancer mortality, respectively, both corresponding to >50% lower risk per 1 MET increase. Lee et al assessed the change in CRF<sub>e</sub>, as related to CVD mortality in a cohort of ~14,000 men from the ACLS cohort that performed two exercise tests.<sup>17</sup> Results showed each 1 MET improvement was associated with a 19% reduction in CVD mortality. Zhang et al also assessed men of the ACLS cohort, examining the relationship between the change in CRF<sub>e</sub> and cancer mortality.<sup>16</sup> Results showed a 5% lower risk of cancer mortality with each 1 MET increase. Discrepancies in the findings between studies may be due to differences in cohort characteristics, the time period between tests, as well as methodological factors such as the different methods used in determining CRF.

A recent 2016 AHA scientific statement advocated that CRF should be considered a clinical vital sign.<sup>9</sup> The findings from the current study demonstrate the value of periodic measurement of CPX-CRF as the change in CPX-CRF over time was found to improve mortality risk assessment compared to one-time measure. In a cross-sectional analysis using the current cohort assessing the relationship between baseline CPX-CRF and all-cause mortality, there was an 11.6% lower risk per MET increment difference, which was similar to the 13% lower risk of all-cause mortality per MET increment difference reported in a review by Kodama et al of 33

studies assessing the cross-sectional relationship between CRF and mortality.<sup>3, 7</sup> However, the magnitude of the association between the change in CRF and all-cause mortality was found to be greater than that found using a single measure, with a nearly 27% lower risk per MET increase between CPX1 and CPX2. The smaller magnitude of the association found in these cross-sectional analyses may be a result of the lack of information on changes in CRF over time, especially since an expected response to identification of low CRF would be to begin or increase exercise training. To further highlight the importance of routine CRF assessment, CRF measures taken at CPX1 and CPX2 were compared as predictors of mortality. The CPX2 CRF was found to be a stronger predictor of all-cause mortality compared with the CPX1 CRF measure.

On average, CRF declines at least 1 MET per decade of age<sup>22, 39</sup> and the current study suggests that attenuating this decline is associated with reduced risk of mortality. Regular PA can help mitigate this age-related reduction to preserve an adequate/acceptable CRF level for one's age and sex. PA behavior accounts for approximately 50% of the variation in CRF and it has been reported that individuals beginning a moderate to vigorous aerobic exercise program can increase their CRF by approximately 1 to 2 METs.<sup>8, 35, 40</sup> On the contrary, those that reduce their PA over time can experience lifestyle related declines in CRF, greater than normally experienced due to increasing age.<sup>41</sup> These changes in PA behavior, influencing changes in CRF may potentially alter mortality risk over time. These results can be seen as encouraging for individuals that have low CRF, as they suggest CRF improvements, achievable through regular PA/exercise, can reduce mortality risk.

### *Strengths and Limitations*

The study used CPX, the gold standard method for measuring CRF, providing an accurate representation of the change in CRF over time. Additionally, the BALL ST cohort

consisted of men and women across a wide distribution of age and risk factors. Therefore, the results may be more representative of the population that clinicians see on a regular basis, enhancing utilization in clinical practice. Sex-specific analyses were also performed when assessing all-cause mortality, compared to most studies including both men and women, which have solely adjusted for sex in statistical models. This cohort allows for a better understanding of how changes in CPX-CRF may influence prognosis differently in men and women. Finally, the study had an extensive mortality follow-up of 17.7 years, which adds to the knowledge base of the impact changes in CRF across time have on mortality risk.

The limitations of the present study include a > 90% non-Hispanic white cohort. Future work is needed to confirm these findings in populations from diverse racial and ethnic backgrounds that are known to influence health outcomes.<sup>42</sup> Additionally, statistical power was reduced for sex-specific analyses when assessing disease-specific mortality, therefore men and women were only analyzed independently when assessing all-cause mortality outcomes. Future studies should assess the association between the change in CRF and CVD and cancer-specific mortality in a large cohort of men and women with greater disease-specific mortality end-points.

## **Conclusion**

Change in CPX-CRF over time was inversely related to all-cause, CVD, and cancer mortality in a cohort of apparently healthy adults. This relationship was strengthened when accounting for the change in traditional CVD risk factors, further demonstrating the importance of CRF for determining health outcomes. These findings support the clinical value of CPX-CRF and highlight the importance of its routine measurement in clinical practice. Although clinicians should encourage all to participate in regular PA/exercise, as a way to help improve or maintain adequate CRF levels, these findings may be particularly promising to those identified as low fit, as they suggest even small improvements in CRF can have a profoundly positive impact on reducing mortality risk.



## References

1. Arena R, McNeil A, Sagner M and Lavie CJ. Healthy Living: The Universal and Timeless Medicine for Healthspan. *Progress in Cardiovascular Diseases*. 2017;59:419-421.
2. Arena R, Bond S, O'Neill R, Laddu DR, Hills AP, Lavie CJ and McNeil A. Public Park Spaces as a Platform to Promote Healthy Living: Introducing a HealthPark Concept. *Progress in Cardiovascular Diseases*. 2017;60:152-158.
3. Imboden MT, Harber MP, Whaley MH, Finch WH, Bishop DL and Kaminsky LA. Cardiorespiratory Fitness and Mortality in Healthy Men and Women. *Journal of the American College of Cardiology*. 2018;72:2283-2292.
4. Blair SN, Kohl HW, Paffenbarger RS, Clark DG, Cooper KH and Gibbons LW. Physical fitness and all-cause mortality: A prospective study of healthy men and women. *Journal of the American Medical Association*. 1989;262:2395-2401.
5. Myers J, Prakash M, Froelicher V, Do D, Partington S and Atwood JE. Exercise Capacity and Mortality among Men Referred for Exercise Testing. *New England Journal of Medicine*. 2002;346:793-801.
6. Laukkanen JA, Lakka TA, Rauramaa R, Kuhanen R, Venalainen JM, Salonen R and Salonen JT. Cardiovascular fitness as a predictor of mortality in men. *Archives of Internal Medicine*. 2001;161:825-831.
7. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi MF, Sugawara A, Totsuka KF, Shimano H, Ohashi Y, Yamada N and Sone H. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *Journal of the American Medical Association*. 2009;301:2024-2035.
8. Fletcher GF, Landolfo C, Niebauer J, Ozemek C, Arena R and Lavie CJ. Promoting Physical Activity and Exercise: JACC Health Promotion Series. *Journal of the American College of Cardiology*. 2018;72:1622-1639.
9. Ross R, Blair SN, Arena R, Church TS, Depres J-P, Franklin B, L. HW, Kaminsky LA, Levine BJ, Lavie CJ, Myers J, Niebauer J, Sallis R, Sawada S, Sui X and Wisloff U. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign. *Circulation*. 2016;134:e653-699.

10. Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee DC, Earnest CP, Church TS, O'Keefe JH, Milani RV and Blair SN. Exercise and the cardiovascular system: Clinical science and cardiovascular outcomes. . *Circulation Research*. 2015;117:209-219.
11. Wisloff U and Lavie CJ. Taking Physical Activity, Exercise, and Fitness to a Higher Level. *Progress in Cardiovascular Diseases*. 2017;60:1-2.
12. Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs DR, Jr. and Liu K. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. *Journal of the American Medical Association*. 2003;290:3092-3100.
13. Martin BJ, Arena R, Haykowsky M, Hauer T, Austford LD, Knudtson M, Aggarwal S and Stone JA. Cardiovascular fitness and mortality after contemporary cardiac rehabilitation. *Mayo Clinic Proceedings*. 2013;88:455-463.
14. Sui X, Sarzynski MA, Lee DC and Kokkinos PF. Impact of Changes in Cardiorespiratory Fitness on Hypertension, Dyslipidemia and Survival: An Overview of the Epidemiological Evidence. *Progress in Cardiovascular Diseases*. 2017;60:56-66.
15. Laukkanen JA, Zaccardi F, Khan H, Kurl S, Jae SY and Rauramaa R. Long-term Change in Cardiorespiratory Fitness and All-Cause Mortality: A Population-Based Follow-up Study. *Mayo Clinic Proceedings*. 2016;91:1183-1188.
16. Zhang P, Sui X, Hand GA, Hebert JR and Blair SN. Association of changes in fitness and body composition with cancer mortality in men. *Medicine and Science in Sports and Exercise*. 2014;46:1366-1374.
17. Lee DC, Sui X, Artero EG, Lee IM, Church TS, McAuley PA, Stanford FC, Kohl HW, 3rd and Blair SN. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. *Circulation*. 2011;124:2483-2490.
18. Blair SN, Kohl HW, Barlow CE, Paffenbarger RS, Gibbons LW and Macera CA. Changes in physical fitness and all-cause mortality: a prospective study of healthy and unhealthy men. *Journal of the American Medical Association*. 1995;273:1093-1098.
19. Kokkinos P, Myers J, Faselis C, Panagiotakos DB, Doumas M, Pittaras A, Manolis A, Kokkinos JP, Karasik P, Greenberg M, Papademetriou V and Fletcher R. Exercise capacity and mortality in older men: a 20-year follow-up study. *Circulation*. 2010;122:790-797.

20. Shah RV, Murthy VL, Colangelo LA, Reis J, Venkatesh BA, Sharma R, Abbasi SA, Goff DC, Jr., Carr JJ, Rana JS, Terry JG, Bouchard C, Sarzynski MA, Eisman A, Neilan T, Das S, Jerosch-Herold M, Lewis CE, Carnethon M, Lewis GD and Lima JA. Association of Fitness in Young Adulthood With Survival and Cardiovascular Risk: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. *JAMA Internal Medicine*. 2016;176:87-95.
21. Erikssen G, Liestol K, Bjornholt J, Thaulow E, Sandvik L and Erikssen J. Changes in physical fitness and changes in mortality. *Lancet*. 1998;352:759-762.
22. Kaminsky LA, Arena R and Myers J. Reference Standards for Cardiorespiratory Fitness Measured With Cardiopulmonary Exercise Testing: Data From the Fitness Registry and the Importance of Exercise National Database. *Mayo Clinic Proceedings*. 2015;90:1515-1523.
23. Kaminsky LA, Arena R, Beckie TM, Brubaker PH, Church TS, Forman DE, Franklin BA, Gulati M, Lavie CJ, Myers J, Patel MJ, Pina IL, Weintraub WS and Williams MA. The importance of cardiorespiratory fitness in the United States: the need for a national registry: a policy statement from the American Heart Association. *Circulation*. 2013;127:652-62.
24. Harber MP, Kaminsky LA, Arena R, Blair SN, Franklin BA, Myers J and Ross R. Impact of Cardiorespiratory Fitness on All-Cause and Disease-Specific Mortality: Advances Since 2009. *Progress in Cardiovascular Diseases*. 2017;60:11-20.
25. Guazzi M, Arena R, Halle M, Piepoli M, Myers J and Lavie CJ. 2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. *Circulation*. 2016;133:e694-711.
26. Whaley MH, Kaminsky LA, Dwyer GB and Getchell LH. Failure of predicted VO<sub>2</sub>peak to discriminate physical fitness in epidemiological studies. *Med Sci Sports Exerc*. 1995;27:85-91.
27. Whaley MH, Kaminsky LA, Dwyer GB, Getchell LH and Norton JA. Predictors of over- and underachievement of age-predicted maximal heart rate. *Medicine and Science in Sports and Exercise*. 1992;24:1173-1179.
28. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans. 2008.
29. American College of Sports Medicine. *ACSM's guidelines for exercise testing and prescription*. 10th ed. Philadelphia, PA: Wolters Kluwer; 2017.

30. Myers J, Forman DE, Balady GJ, Franklin BA, Nelson-Worel J, Martin B-J, Herbert WG, Guazzi M and Arena R. Supervision of exercise testing by nonphysicians: a scientific statement from the American Heart Association. *Circulation*. 2014;130:1014-1027.
31. National Center for Health Statistics. The international classification of diseases, 10th revision: ICD 10. 1992.
32. National Center for Health Statistics. The international classification of diseases, 9th revision, clinical modification. 1978.
33. Myers J. *Essentials of Cardiopulmonary Exercise Testing*. Champaign, IL: Human Kinetics; 1996.
34. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD and Williams MA. Exercise standards for testing and training: a scientific statement from the american heart association. *Circulation*. 2013;128:873-934.
35. Bouchard C, An P, Rice T, Skinner JS, Wilmore JH, Gagnon J, Perusse L, Leon AS and Rao DC. Familial aggregation of VO(2max) response to exercise training: results from the HERITAGE Family Study. *Journal of Applied Physiology*. 1999;87:1003-1008.
36. Kaminsky LA, Imboden MT, Arena R and Myers J. Reference Standards for Cardiorespiratory Fitness Measured With Cardiopulmonary Exercise Testing Using Cycle Ergometry: Data From the Fitness Registry and the Importance of Exercise National Database (FRIEND) Registry. *Mayo Clinic Proceedings*. 2017;92:228-233.
37. Kokkinos P, Myers J, Franklin BA, Narayan P, Lavie CJ and Faselis C. Cardiorespiratory fitness and health outcomes: A call to standardize fitness categories. *Mayo Clinic Proceedings*. 2017;92:in press.
38. Nauman J, Tauschek LC, Kaminsky LA, Nes BM and Wisloff U. Global Fitness Levels: Findings From a Web-Based Surveillance Report. *Progress in Cardiovascular Diseases*. 2017;60:78-88.
39. Aspenes ST, Nilsen TI, Skaug E-A, Bertheussen GF, Ellingsen O, Vatten L and Wisloff U. Peak oxygen uptake and cardiovascular risk factors in 4631 healthy women and men. *Medicine and Science in Sports and Exercise*. 2011;43:1465-1473.

40. Skinner JS, Jaskolska A, Krasnoff J, Gagnon J, Leon AS, Rao DC, Wilmore JH and Bouchard C. Age, sex, race, initial fitness, and response to training: the HERITAGE Family Study. *Journal of Applied Physiology*. 2001;90:1770-1776.
41. Neuffer PD. The effect of detraining and reduced training on the physiological adaptations to aerobic exercise training. *Sports Medicine*. 1989;8:302-320.
42. Swift DL, Johannsen NM, Earnest CP, Newton RL, Jr., McGee JE and Church TS. Cardiorespiratory Fitness and Exercise Training in African Americans. *Progress in Cardiovascular Diseases*. 2017;60:96-102.

**Table 1. Descriptive characteristics of the BALL ST Cohort at CPX1**

	Men (n=552)	Women (n=281)
Age (years)	44.6 ± 9.8	45.0 ± 10.8
VO <sub>2peak</sub> (mL·kg <sup>-1</sup> ·min <sup>-1</sup> )	36.6 ± 9.3*	27.8 ± 7.3
VO <sub>2peak</sub> (L·min <sup>-1</sup> )	3.10 ± 0.03*	1.90 ± 0.04
METs	10.8 ± 2.7*	8.3 ± 2.2
FRIEND percentile <sup>7,8</sup>	46 ± 26	54±25
Weight (kg)	87.2± 16.8*	69.5± 14.6
BMI (kg·m <sup>-2</sup> )	27.2 ± 4.7	26.0± 5.7
Waist (cm)	84.5±32.1	80.1±12.8
Blood glucose (mg·dL <sup>-1</sup> )	98.1±28.5*	94.0±19.3
Total cholesterol (mg·dL <sup>-1</sup> )	212.1±46.2	202.2± 39.2
SBP/DBP (mmHg)	126*/81* ± 13/9	119/76 ± 16/11
RHR (bpm)	68 ± 13	72 ± 11
HR <sub>max</sub> (bpm)	176 ± 16	177 ± 14
Risk Factors		
Obesity (%)	22	24
Impaired fasting glucose (%)	31	26
Dyslipidemia (%)	61*	36
Hypertension (%)	32*	21
Physical inactivity (%)	62*	77
Smoking (%)	12*	6

Abbreviations: BALL ST, Ball State Adult fitness program Longitudinal Lifestyle Study (BALL ST) cohort; BMI, body mass index; DBP, diastolic blood pressure; FRIEND, Fitness Registry and the Importance of Exercise National Database; HR<sub>max</sub>, maximal heart rate; METs, metabolic equivalents; RHR, resting heart rate; SBP, systolic blood pressure; VO<sub>2peak</sub>, peak oxygen consumption. Prevalence of obesity, impaired fasting glucose, dyslipidemia, hypertension, and physical inactivity was defined per current accepted atherosclerotic CVD risk factor criteria.<sup>29</sup>

\*  $p \leq 0.05$

Data are expressed as mean ± SD or %.

**Table 2. Descriptive Characteristics at CPX1 of the Living and Deceased participants within the BALL ST cohort**

	Men		Women	
	Living (n=420)	Deceased (n=132)	Living (n=241)	Deceased (n=40)
Age (years)	42.8 ± 9.8*	49.3 ± 8.7	43.1 ± 10.4*	51.8 ± 12.0
RHR (bpm)	69 ± 13	64 ± 16	72 ± 11	71 ± 11
HR <sub>max</sub> (bpm)	178 ± 16	173 ± 16	179 ± 13*	169 ± 19
VO <sub>2peak</sub> (mL·kg <sup>-1</sup> ·min <sup>-1</sup> )	37.2 ± 9.6*	34.1 ± 8.3	28.4 ± 7.6	27.2 ± 6.9
VO <sub>2peak</sub> (L·min <sup>-1</sup> )	3.19 ± 0.66*	2.80 ± 0.65	1.92 ± 0.42	1.83 ± 0.46
METs	10.7 ± 2.7*	9.7 ± 2.2	8.1 ± 2.2	7.8 ± 2.0
FRIEND percentile <sup>7,8</sup>	47 ± 27	44 ± 24	54 ± 25	57 ± 25
Weight (kg)	87.6 ± 17.2*	83.7 ± 14.0	69.2 ± 14.4	68.0 ± 15.1
BMI (kg·m <sup>-2</sup> )	27.4 ± 4.8	26.3 ± 3.9	25.7 ± 5.6	25.9 ± 5.8
Waist (cm)	94.8 ± 12.6	93.3 ± 9.0	79.9 ± 12.6	79.5 ± 14.3
Blood glucose (mg·dL <sup>-1</sup> )	97.8 ± 28.0	95.3 ± 25.7	93.7 ± 21.0	94.8 ± 11.5
Total cholesterol (mg·dL <sup>-1</sup> )	207.3 ± 45.2*	228.5 ± 45.7	199.7 ± 38.9*	217.3 ± 37.8
SBP/DBP (mmHg)	125*/81 ± 13/9	129/83 ± 12/9	118*/76* ± 14/10	127/80 ± 19/12
Risk Factors				
Obesity (%)	25*	12	24*	20
Diabetes (%)	31	35	27*	22
Dyslipidemia (%)	59*	68	34*	45
Hypertension (%)	32	32	20*	30
Physical inactivity (%)	59*	68	75*	85
Smoking (%)	11*	16	5	6

Abbreviations: BALL ST, Ball State Adult Fitness Program Longitudinal Lifestyle Study (BALL ST) cohort; BMI, body mass index; CPX, cardiopulmonary exercise testing; DBP, diastolic blood pressure; FRIEND, Fitness Registry and the Importance of Exercise National Database; HR<sub>max</sub>, maximal heart rate; METs, metabolic equivalents; RHR, resting heart rate; SBP, systolic blood pressure; VO<sub>2peak</sub>, peak oxygen consumption. Prevalence of obesity, impaired fasting glucose, dyslipidemia, hypertension, and physical inactivity was defined per current accepted atherosclerotic CVD risk factor criteria.<sup>29</sup>

\*  $p \leq 0.05$ , living vs. deceased

Data are expressed as mean ± SD or %.

**Table 3a. Hazard ratios for all-cause, CVD, and cancer mortality outcomes for BALL-ST cohort according to change in CRF, expressed as both  $\text{VO}_{2\text{peak}}$  and METs.**

<i>Mortality</i>	Hazard Ratio (95% CI)	% reduction/ $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$	% reduction / MET
All-cause mortality			
Model 1	0.923 <sup>*</sup> (0.953 – 0.972)	7.7	27.0
Model 2	0.889 <sup>*</sup> (0.873 – 0.926)	11.1	38.9
Model 3	0.892 <sup>*</sup> (0.843 – 0.943)	10.8	37.8
CVD mortality			
Model 1	0.900 <sup>*</sup> (0.863 – 0.939)	10.0	35.0
Model 2	0.886 <sup>*</sup> (0.840 – 0.935)	11.4	39.9
Model 3	0.853 <sup>†</sup> (0.750 – 0.971)	14.7	51.5
Cancer mortality			
Model 1	0.924 <sup>†</sup> (0.887 – 0.962)	7.6	26.6
Model 2	0.894 <sup>*</sup> (0.849 – 0.942)	10.6	27.1
Model 3	0.861 <sup>*</sup> (0.774 – 0.957)	15.9	55.7



**Table 3b. Hazard ratios for all-cause mortality outcomes for men and women according to change in CRF, expressed as both  $VO_{2peak}$  and METs.**

All-cause mortality	Hazard Ratio (95% CI)	% reduction/ $ml \cdot kg^{-1} \cdot min^{-1}$	% reduction/ MET
<i>Men</i>			
Model 1	0.934* (0.911 – 0.957)	6.6	23.1
Model 2	0.903* (0.874 – 0.933)	9.7	34.0
Model 3	0.899* (0.842 – 0.960)	10.1	35.4
<i>Women</i>			
Model 1	0.897* (0.929 – 0.999)	10.3	36.1
Model 2	0.887* (0.825 – 0.953)	11.3	39.6
Model 3	0.922 (0.793 – 1.072)	7.8	27.3

Abbreviations: CRF=cardiorespiratory fitness; CVD=cardiovascular disease;  $VO_{2peak}$ = peak oxygen consumption.

\*  $p \leq 0.01$

†  $p \leq 0.05$

Model 1 adjusted for years since first CPX; Model 2 adjusted for years since first CPX, CPX1  $VO_{2peak}$ , and age in the sex-specific analyses with the addition of sex in the overall sample; Model 3 adjusted for years since first CPX, CPX1  $VO_{2peak}$ , age, examination year, and change in risk factors (dyslipidemia, hypertension, impaired fasting glucose, obesity, physical inactivity, and smoking) for the sex-specific analyses with the addition of sex when models were obtained for the overall sample.

**Table 4. Absolute parameter estimates comparing the relationship between CPX1  $VO_{2peak}$  and CPX2  $VO_{2peak}$  in the cox model to mortality outcomes with Wald Chi-square test of equality.**

	Absolute parameter estimate CPX1	Absolute parameter estimate CPX2	<i>p</i>
Model 1	0.014	0.052*	0.001
Model 2	0.006	0.029*	0.001

Abbreviations: CPX, cardiopulmonary exercise testing;  $VO_{2peak}$ , peak oxygen consumption

\*Comparison of the coefficients for CPX1  $VO_{2peak}$  to  $VO_{2peak}$  measured at CPX2.

Model 1 run unadjusted; Model 2 adjusted for years since first CPX, CPX1  $VO_{2peak}$ , age, and sex.

Funding: Support for this project was provided, in part, from an American Heart Association Award #AIREA33930023 (M. Harber, PI).

Disclosures: L. Kaminsky serves as a Scientific Advisor for ENDO Medical, Inc.

ACCEPTED MANUSCRIPT